AU2010259939B2 - Diketopiperazine microparticles with defined isomer contents - Google Patents

Diketopiperazine microparticles with defined isomer contents Download PDF

Info

Publication number
AU2010259939B2
AU2010259939B2 AU2010259939A AU2010259939A AU2010259939B2 AU 2010259939 B2 AU2010259939 B2 AU 2010259939B2 AU 2010259939 A AU2010259939 A AU 2010259939A AU 2010259939 A AU2010259939 A AU 2010259939A AU 2010259939 B2 AU2010259939 B2 AU 2010259939B2
Authority
AU
Australia
Prior art keywords
fdkp
microparticles
trans isomer
isomer content
diketopiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010259939A
Other languages
English (en)
Other versions
AU2010259939A1 (en
Inventor
Kelly S. Kraft
Karla Somerville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of AU2010259939A1 publication Critical patent/AU2010259939A1/en
Application granted granted Critical
Publication of AU2010259939B2 publication Critical patent/AU2010259939B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2010259939A 2009-06-12 2010-06-11 Diketopiperazine microparticles with defined isomer contents Active AU2010259939B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18677909P 2009-06-12 2009-06-12
US61/186,779 2009-06-12
PCT/US2010/038287 WO2010144785A2 (en) 2009-06-12 2010-06-11 Diketopiperazine microparticles with defined isomer contents

Publications (2)

Publication Number Publication Date
AU2010259939A1 AU2010259939A1 (en) 2011-12-15
AU2010259939B2 true AU2010259939B2 (en) 2012-07-05

Family

ID=43306942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010259939A Active AU2010259939B2 (en) 2009-06-12 2010-06-11 Diketopiperazine microparticles with defined isomer contents

Country Status (17)

Country Link
US (1) US8227409B2 (cg-RX-API-DMAC10.html)
EP (2) EP2440186B1 (cg-RX-API-DMAC10.html)
JP (2) JP5859432B2 (cg-RX-API-DMAC10.html)
KR (1) KR101782174B1 (cg-RX-API-DMAC10.html)
CN (1) CN102458371B (cg-RX-API-DMAC10.html)
AR (1) AR077087A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010259939B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1010722B1 (cg-RX-API-DMAC10.html)
CA (1) CA2765156C (cg-RX-API-DMAC10.html)
ES (2) ES2880102T3 (cg-RX-API-DMAC10.html)
IL (1) IL216910A (cg-RX-API-DMAC10.html)
MX (1) MX2011013313A (cg-RX-API-DMAC10.html)
MY (1) MY172858A (cg-RX-API-DMAC10.html)
RU (1) RU2490026C1 (cg-RX-API-DMAC10.html)
SG (4) SG10201403147SA (cg-RX-API-DMAC10.html)
TW (1) TWI513692B (cg-RX-API-DMAC10.html)
WO (1) WO2010144785A2 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US20070027063A1 (en) * 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
ES2302448B1 (es) * 2006-10-20 2009-05-08 Vodafone España, S.A. Sistema y metodo de difusion de informacion de area en entornos locales de tamaño reducido dentro de un sistema celular de comunicaciones moviles.
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) * 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US9968125B2 (en) 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
IL260823B2 (en) * 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler
WO2021202425A1 (en) 2020-03-28 2021-10-07 University Of Louisville Research Foundation, Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018754A1 (en) * 1992-03-11 1993-09-30 Pharmaceutical Discovery Corporation Self-assembling diketopiperazine drug delivery system
WO2006086107A2 (en) * 2005-01-10 2006-08-17 Mannkind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2006105501A2 (en) * 2005-03-31 2006-10-05 Mannkind Corporation Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
US20070196503A1 (en) * 2006-02-22 2007-08-23 Wilson Bryan R Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
PL343342A1 (en) 1998-04-09 2001-08-13 Axiva Gmbh Particulate active agent support for pulmonary application
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
WO2005092301A1 (en) 2004-03-26 2005-10-06 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) * 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
RU2409349C2 (ru) 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
KR20100090692A (ko) * 2007-10-24 2010-08-16 맨카인드 코포레이션 활성제의 전달
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
MY155524A (en) * 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018754A1 (en) * 1992-03-11 1993-09-30 Pharmaceutical Discovery Corporation Self-assembling diketopiperazine drug delivery system
WO2006086107A2 (en) * 2005-01-10 2006-08-17 Mannkind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2006105501A2 (en) * 2005-03-31 2006-10-05 Mannkind Corporation Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
US20070196503A1 (en) * 2006-02-22 2007-08-23 Wilson Bryan R Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
WO2007098500A2 (en) * 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

Also Published As

Publication number Publication date
KR101782174B1 (ko) 2017-09-26
JP5859432B2 (ja) 2016-02-10
TWI513692B (zh) 2015-12-21
JP2016028068A (ja) 2016-02-25
ES2880102T3 (es) 2021-11-23
MX2011013313A (es) 2012-01-25
SG195546A1 (en) 2013-12-30
CN102458371A (zh) 2012-05-16
AU2010259939A1 (en) 2011-12-15
ES2751107T3 (es) 2020-03-30
SG176778A1 (en) 2012-01-30
CA2765156A1 (en) 2010-12-16
US8227409B2 (en) 2012-07-24
EP2440186B1 (en) 2019-08-07
TW201113259A (en) 2011-04-16
SG10201403147SA (en) 2014-10-30
IL216910A0 (en) 2012-02-29
CA2765156C (en) 2018-04-10
EP3556356A1 (en) 2019-10-23
BRPI1010722A2 (pt) 2016-03-15
SG10201706995VA (en) 2017-09-28
WO2010144785A3 (en) 2011-03-03
KR20120044971A (ko) 2012-05-08
IL216910A (en) 2016-05-31
EP3556356B1 (en) 2021-05-05
BRPI1010722B1 (pt) 2019-12-10
EP2440186A2 (en) 2012-04-18
MY172858A (en) 2019-12-12
JP6101326B2 (ja) 2017-03-22
CN102458371B (zh) 2015-08-05
AR077087A1 (es) 2011-08-03
RU2490026C1 (ru) 2013-08-20
RU2012100785A (ru) 2013-07-20
WO2010144785A2 (en) 2010-12-16
JP2012530062A (ja) 2012-11-29
US20100317574A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
CA2765156C (en) Diketopiperazine microparticles with defined isomer contents
US12383552B2 (en) Diketopiperazine microparticles with defined specific surface areas
AU2015203688B2 (en) Diketopiperazine microparticles with defined specific surface areas
HK40016337A (en) Diketopiperazine microparticles with defined isomer content
HK40016337B (en) Diketopiperazine microparticles with defined isomer content
HK1168280A (en) Diketopiperazine microparticles with defined isomer contents
HK1168280B (en) Diketopiperazine microparticles with defined isomer contents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)